
简介:
- 作者: Shuqian Zhang, Liting Song, Bo Yuan, Cheng Zhang, Jixin Cao, Jinlong Chen, Jiayi Qiu, Yilin Tai, Jingqi Chen,Zilong Qiu,Xing-Ming Zhao, and Tian-Lin Cheng
- 杂志: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-023-36004-2
- 出版日期: 2023 Jan 26
论文中使用的产品/服务
Quotation shows PackGene:5 μl of AAV(1E + 13GC/ml, from PackGene Biotech) were mixed with 5% fast green into the injection syringe. Injection sites at 2/5 of the distance from the lambda suture to each eye were selected for AAV intraventricular injection.
Research Field:miniature CRISPR-Cas12f systems
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:The Postnatal day 0 (P0) C57BL/6 Mus musculus (Vital River Laboratories) was used in this study.
摘要
Although miniature CRISPR-Cas12f systems were recently developed, the editing efficacy and targeting range of derived miniature cytosine and adenine base editors (miniCBEs and miniABEs) have not been comprehensively addressed. Moreover, functional miniCBEs have not yet be established. Here we generate various Cas12f-derived miniCBEs and miniABEs with improved editing activities and diversified targeting scopes. We reveal that miniCBEs generated with traditional cytidine deaminases exhibit wide editing windows and high off-targeting effects. To improve the editing signatures of classical CBEs and derived miniCBEs, we engineer TadA deaminase with mutagenesis screening to generate potent miniCBEs with high precision and minimized off-target effects. We show that newly designed miniCBEs and miniABEs are able to correct pathogenic mutations in cell lines and introduce genetic mutations efficiently via adeno-associated virus delivery in the brain in vivo. Together, this study provides alternative strategies for CBE development, expands the toolkits of miniCBEs and miniABEs and offers promising therapeutic tools for clinical applications.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。
